Compare OXSQ & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | OXSQ | ACOG |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.9M | 193.6M |
| IPO Year | 2003 | 2024 |
| Metric | OXSQ | ACOG |
|---|---|---|
| Price | $1.33 | $9.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 1.5M | 162.7K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 22.83% | N/A |
| EPS Growth | N/A | ★ 41.58 |
| EPS | ★ 0.10 | N/A |
| Revenue | N/A | ★ $10,220,275.00 |
| Revenue This Year | $3.61 | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | $13.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $4.50 |
| 52 Week High | $2.21 | $10.14 |
| Indicator | OXSQ | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 36.62 | 49.78 |
| Support Level | $1.30 | $8.92 |
| Resistance Level | $1.43 | $10.14 |
| Average True Range (ATR) | 0.04 | 0.58 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 18.97 | 12.10 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize portfolio's total return. Its primary current focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and, to a lesser extent collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. CLO investments may also include warehouse facilities, which are early-stage CLO vehicles intended to aggregate loans that may be used to form the basis of a traditional CLO vehicle. The company may also invest in publicly traded debt and/or equity securities.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.